{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:19:39Z","timestamp":1771550379169,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T00:00:00Z","timestamp":1132617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold>The purpose of this prospective study was to investigate whether amphotericin B (AmB) had any potential role in the systemic chemotherapy of primary hepatic malignancy using cancer cells collected by the authors\u2019 method of primary culture.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>The specimens obtained by ultrasound\u2010guided fine\u2010needle aspiration biopsy (22\u2003G) from 15 patients with hepatocellular carcinoma (HCC) and one with cholangiocarcinoma were plated into culture flask without disaggregation by trypsin\u2010ethylenediamine tetra\u2010acetic acid solution. Six patients with HCC and one patient with cholangiocarcinoma (7\/16, 44%) had successful culture and the cancer cells at the 4th passage were continuously exposed to therapeutic ranges of epirubicin (0, 0.5, 1.0, 1.5, 2.0\u2003\u00b5g\/mL) with or without the combination of 2.5\u2003\u00b5g\/mL AmB for 24\u2003h. 3\u2010(4,5\u2010Dimethylthiazol\u20102\u2010yl)\u20102,5\u2010diphenyltetrazolium bromide (MTT) assay was applied to evaluate the effects of the drugs. A human HCC cell line (HA 22T\/VGH) was studied for comparison.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>Addition of AmB showed no influence on epirubicin cytotoxicity in two patients (one partial resistant HCC and one epirubicin\u2010sensitive cholangiocarcinoma; 25%), augmentation of the epirubicin cytotoxicity in two patients (one total resistant HCC, partial resistant HA 22T\/VGH cell line and one epirubicin\u2010sensitive HCC; 37.5%), and decrease of epirubicin cytotoxicity in the remaining three (one partial resistant and two epirubicin\u2010sensitive HCC; 37.5%).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold>Amphotericin B has a discordant influence on epirubicin cytotoxicity in primary cultured hepatic malignant cells. Application of AmB in the systemic chemotherapy of primary hepatic malignancy should be limited to patients with positive AmB effect evaluated by an<jats:italic>in vitro<\/jats:italic>sensitivity test such as the present method.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2005.04026.x","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T10:27:11Z","timestamp":1140776831000},"page":"398-405","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique"],"prefix":"10.1111","volume":"21","author":[{"given":"ZU\u2010YAU","family":"LIN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WAN\u2010LONG","family":"CHUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YEN\u2010HWANG","family":"CHUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MING\u2010LUNG","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MING\u2010YUH","family":"HSIEH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIANG\u2010YEN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUNG\u2010FA","family":"TSAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-68349-0_24"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-68349-0_31"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345050-00011"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00307-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753030-00008"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(90)90014-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199506000-00011"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/oxfordjournals.annonc.a058356","article-title":"Randomized phase II study of single\u2010agent epirubicin +\/\u2013 verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society","volume":"4","author":"Mross K","year":"1993","journal-title":"Ann. Oncol."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1771"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.1996.14.4.1165","article-title":"Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial","volume":"14","author":"Dogliotti L","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_12_2","first-page":"959","article-title":"Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and L1210 leukemia","volume":"43","author":"Ozols RF","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_6_13_2","first-page":"4097","article-title":"Effect of amphotericin B on adriamycin transport in P388 cells","volume":"45","author":"Krishan A","year":"1985","journal-title":"Cancer Res."},{"key":"e_1_2_6_14_2","first-page":"6054","article-title":"Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1\u2010(2\u2010chloroethyl)\u20103\u2010cyclohexyl\u20101\u2010nitrosourea against the human promyelocytic leukemia cell line HL\u201060","volume":"46","author":"Vertut\u2010Croquin A","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(89)90002-9"},{"key":"e_1_2_6_16_2","first-page":"1039","article-title":"Effects of antimicrobial drugs on the cytotoxicity of epirubicin, bleomycin, estramustine and cisplatin","volume":"11","author":"Bergstrom P","year":"1991","journal-title":"Anticancer Res."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1991.tb01912.x"},{"key":"e_1_2_6_18_2","first-page":"3302","article-title":"Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin\u2010resistant human lung cancer cell lines","volume":"53","author":"Morikage T","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_19_2","first-page":"891","article-title":"Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis\u2010diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells","volume":"13","author":"Kikkawa F","year":"1993","journal-title":"Anticancer Res."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.362"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1994.tb02922.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689453"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050675"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0090-9556(24)14949-5","article-title":"Enhancement of platinum\u2010drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum\u2010resistant variant by liposomal amphotericin B and phospholipase A2\u2013II","volume":"27","author":"Ferguson PJ","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_6_25_2","first-page":"335","article-title":"Reversal of carboplatin resistance in human laryngeal carcinoma cells","volume":"46","author":"Vukovic L","year":"1999","journal-title":"Neoplasma"},{"key":"e_1_2_6_26_2","first-page":"1565","article-title":"Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma","volume":"62","author":"Krutchik AN","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840115)53:2<214::AID-CNCR2820530205>3.0.CO;2-K"},{"key":"e_1_2_6_28_2","first-page":"651","article-title":"Effects of amphotericin B with combination chemotherapy on response rates and on survival in non\u2010small cell carcinoma of the lung","volume":"68","author":"Presant CA","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90263-X"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199308000-00012"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00304769"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.23.040183.001511"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005020-00003"},{"key":"e_1_2_6_34_2","first-page":"125","volume-title":"Animal Cell Culture","author":"Morasca L","year":"1986"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(00)00189-2"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-68349-0_21"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2005.04026.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2005.04026.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:29:39Z","timestamp":1736285379000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2005.04026.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1111\/j.1440-1746.2005.04026.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2005.04026.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"2006-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}